The MOTS-c benefits on record are mouse benefits: better insulin sensitivity, less diet-induced obesity, more stamina. In people the peptide has only ever been measured, never administered. We read the mechanism work as unusually good and the human evidence as absent.
MOTS-c benefits are shown in mice and not in people. The peptide is made inside the mitochondria and switches on AMPK. Treated mice gain insulin sensitivity and stamina. But all human data is observational, and zero trials have given the peptide to a person.
What is MOTS-c, and why does that matter?
Most compounds in a peptide catalog are synthetic analogs of something, or fragments of something larger. MOTS-c is neither.
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA region, discovered at USC in 2015. Mitochondria make it themselves, it circulates in human plasma, and its levels decline with age.
That makes MOTS-c a retrograde signal. Information travels backwards, from the organelle to the cell nucleus, changing which genes switch on when the cell is under metabolic stress.
Before MOTS-c and its sibling humanin, the mitochondrial genome was thought to encode only the electron-transport-chain subunits and its own RNAs.
The endogenous status cuts two ways, and both matter for how you read benefit claims. It's a genuine reason to expect biological relevance. It's also why nobody has a patentable product, which is a large part of why the clinical development below never happened.
How does MOTS-c activate AMPK?
The MOTS-c discovery paper didn't simply observe that the peptide activates AMPK. It described the route. MOTS-c inhibits the folate cycle and the de novo purine synthesis tethered to it, and AMPK activation follows from that metabolic shift. Skeletal muscle was the primary target organ.
The functional consequences in that first paper were substantial and in mice:
- Insulin resistance. MOTS-c treatment prevented both age-dependent and high-fat-diet-induced insulin resistance.
- Obesity. It prevented diet-induced obesity in the same models.
- Muscle. Later work showed it directly binds and activates the kinase CK2, and that the effect is tissue-specific — CK2 is stimulated in muscle and suppressed in fat.
- Atrophy signaling. A separate line found MOTS-c lowers myostatin, the brake on muscle growth, through a CK2–PTEN–mTORC2–AKT–FOXO1 chain.
AMPK is the cell's energy sensor. It switches on when ATP runs low, during exercise, fasting and caloric restriction, and it's also the target of metformin.
A peptide that activates AMPK is standing in a well-mapped part of metabolic biology. That's exactly why the MOTS-c mechanism reads as credible.
Is MOTS-c really an exercise mimetic?
Not on the evidence. The claim rests on two genuine, replicated observations: exercise raises endogenous MOTS-c in human skeletal muscle and in circulation, and administered MOTS-c improves physical performance in mice.
Those mouse gains held at 2, 12 and 22 months of age. Treatment started as late as 23.5 months, given three times a week, still increased physical capacity and healthspan.
In humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation.
Reynolds et al., Nature Communications, 2021The marketing takes a step the literature doesn't: from exercise raising MOTS-c, to taking MOTS-c substituting for exercise.
A 2021 review of mitochondrial-derived peptides and exercise is explicit about this. Studies using an inactivating genetic variant, or combining exercise with MOTS-c treatment, point to distinct and overlapping pathways rather than one standing in for the other.
The same review notes that whether training produces chronic changes in these peptides is conflicting, and depends on the mode, duration and intensity of the plan.
MOTS-c looks like a component of the exercise response signal. A component of a signal isn't a replacement for the stimulus that produced it. No human study has tested whether giving MOTS-c reproduces any training adaptation.
MOTS-c
The same 16-amino-acid mitochondrial-derived peptide used across the mechanism studies cited here, supplied as lyophilized powder with a certificate of analysis matched to the lot.
What human-relevance evidence does MOTS-c have?
The closest MOTS-c gets to human relevance, without anyone being given the peptide, is a naturally occurring variant. K14Q MOTS-c changes a single amino acid. The altered peptide binds CK2 poorly and doesn't produce the effects the normal version does.
In population data, male K14Q carriers showed higher risk of sarcopenia and type 2 diabetes, in an age- and physical-activity-dependent way. Female carriers showed an age-specific reduced risk of type 2 diabetes.
Separately, plasma MOTS-c has been reported to correlate inversely with myostatin in human subjects.
This is real evidence and we weigh it properly. A functionally weaker version of the peptide tracking with worse metabolic outcomes argues that endogenous MOTS-c matters.
It isn't an argument that injecting synthetic MOTS-c corrects anything. That's a different question, and a genetic association can't answer it in either direction.
What human MOTS-c data actually exists?
All the human MOTS-c data is observational, and most of it treats the peptide as a biomarker rather than a treatment.
The largest example is a 2024 hepatitis B study. It recruited 404 patients with HBV infection alongside 85 healthy subjects, and reported circulating MOTS-c correlating negatively with HBV DNA at R = −0.71. The therapeutic half of that paper was done in mice and cells.
That pattern repeats across the literature: measure the peptide in people, treat the animals.
- No randomized trial. No published randomized controlled trial has administered synthetic MOTS-c to humans, for any indication.
- No human pharmacokinetics. Distribution, half-life and clearance for administered MOTS-c are unpublished, so circulating dose recommendations are rodent extrapolations without human validation.
- No human safety dataset. Rodent studies report no obvious toxicity, which is not the same as a characterized safety profile.
The doses that produced functional benefits in mice substantially exceeded physiological levels. So the endogenous-therefore-safe argument doesn't carry: the exposure being proposed isn't the exposure your body produces.
Where is the MOTS-c preclinical case strongest?
Filtered for mechanistic depth rather than headline appeal, four MOTS-c areas stand out. They're unusually coherent for a compound at this evidence tier.
- Skeletal muscle and sarcopenia. The CK2 binding work, the myostatin pathway and the K14Q variant converge on one story.
- Glucose handling. AMPK activation in muscle, plus a gestational-diabetes mouse model, plus the diabetes signal in the variant carriers.
- Fatty liver disease. A 2024 paper reported MOTS-c binds and stabilizes Bcl-2 in steatohepatitis models — a mechanism unrelated to the AMPK story.
- Cancer biology. Tumor suppression reported in ovarian cancer models, alongside Nrf2-dependent protection in radiation injury.
That last pair is where the honest caution sits. The same literature reports anti-tumor effects in one setting and anti-apoptotic, cell-survival effects in another.
Nobody has characterized what chronic MOTS-c exposure does to tumor surveillance in a healthy person, because nobody has given a healthy person chronic exposure in a study.
MOTS-c has been used less frequently in disease treatment, and no effective method of applying MOTS-c in the clinic has been developed.
Zheng et al., Frontiers in Endocrinology, 2023Our read: MOTS-c is the strongest mechanism-to-evidence mismatch in this library. We'd watch it closely rather than treat it as established, and you should hold those two apart.
MOTS-c
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- MOTS-c is endogenous — a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA region, circulating in human plasma and declining with age.
- The mechanism is well mapped: folate-cycle inhibition leading to AMPK activation, direct CK2 binding, and myostatin suppression.
- Administered MOTS-c improved physical capacity in mice at 2, 12 and 22 months, and starting at 23.5 months still extended healthspan.
- Human data is entirely observational. Zero randomized trials of administered MOTS-c have been published, and human pharmacokinetics are unpublished.
- Exercise raises endogenous MOTS-c, which is not the same as MOTS-c replacing exercise — the review literature is explicit that the pathways only partly overlap.
What we're watching
The single event that would move MOTS-c out of this category is a registered Phase 1 trial. The obstacle is commercial rather than scientific: an endogenous peptide is hard to protect, so nobody has an obvious return on the safety package.
We're watching for that filing, and for any published human pharmacokinetic data. We're also watching whether anti-doping bodies move mitochondrial-derived peptides from monitoring onto the Prohibited List.
And we're watching how the dual cancer-biology findings resolve. That duality is the most substantive unanswered safety question in the file.
Frequently asked questions
What are the proven benefits of MOTS-c?
In humans, none have been proven, because no randomized trial has ever given MOTS-c to anyone. In mice, treatment prevented diet-induced obesity and insulin resistance, and improved physical capacity in young, middle-aged and old animals.
Is MOTS-c really an exercise mimetic?
MOTS-c is a component of the exercise response rather than a substitute for it. Exercise raises endogenous MOTS-c in human muscle and blood, and mouse treatment produces some exercise-like adaptations. But the review literature describes distinct and overlapping pathways rather than equivalence.
How does MOTS-c activate AMPK?
Indirectly. The discovery paper reported that MOTS-c inhibits the folate cycle and the de novo purine biosynthesis tethered to it. AMPK activation follows from that metabolic shift, with skeletal muscle as the primary target organ.
Why are there no human trials?
Mostly structure, not skepticism. MOTS-c is endogenous and therefore hard to protect commercially, so no sponsor has funded the pharmacokinetic and safety work a trial would need. As of mid-2026, no registered interventional trial of synthetic MOTS-c has reported.
References
- Lee, C., Zeng, J., Drew, B. G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.009
- Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12, 470. https://doi.org/10.1038/s41467-020-20790-0
- Kumagai, H., Kim, S. J., Miller, B., et al. (2024). MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience, 27(11), 111212. https://doi.org/10.1016/j.isci.2024.111212
- Kumagai, H., Coelho, A. R., Wan, J., et al. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. American Journal of Physiology — Endocrinology and Metabolism, 320(4), E680–E690. https://doi.org/10.1152/ajpendo.00275.2020
- Woodhead, J. S. T., & Merry, T. L. (2021). Mitochondrial-derived peptides and exercise. Biochimica et Biophysica Acta — General Subjects, 1865(12), 130011. https://doi.org/10.1016/j.bbagen.2021.130011
- Zheng, Y., Wei, Z., & Wang, T. (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 14, 1120533. https://doi.org/10.3389/fendo.2023.1120533
- Kim, S. J., Miller, B., Kumagai, H., Silverstein, A. R., Flores, M., & Yen, K. (2020). Mitochondrial-derived peptides in aging and age-related diseases. GeroScience, 43(3), 1113–1121. https://doi.org/10.1007/s11357-020-00262-5
- Lin, C., Luo, L., Xun, Z., et al. (2024). Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection. Gut, 73(2), 338–349. https://doi.org/10.1136/gutjnl-2023-330389
- Lu, H., Fan, L., Zhang, W., et al. (2024). The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Reports, 43(1), 113587. https://doi.org/10.1016/j.celrep.2023.113587
- Yin, Y., Pan, Y., He, J., et al. (2021). The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological Research, 175, 105987. https://doi.org/10.1016/j.phrs.2021.105987
- Yin, Y., Li, Y., Ma, B., et al. (2024). Mitochondrial-derived peptide MOTS-c suppresses ovarian cancer progression. Advanced Science, 11(43), e2405620. https://doi.org/10.1002/advs.202405620
- Zhang, Y., Huang, J., Zhang, Y., et al. (2024). The mitochondrial-derived peptide MOTS-c alleviates radiation pneumonitis via an Nrf2-dependent mechanism. Antioxidants, 13(5), 613. https://doi.org/10.3390/antiox13050613
- Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0